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Abstract: Hepatocellular carcinoma (HCC) represents a major and steadily
increasing global health challenge as the most common primary liver malignancy and leading cause of death in cirrhotic patients. The only hope for curative treatment or significant increase in life expectancy is early d
 etection. Once
patients have progressed towards end-stage HCC, effective treatment options
are extremely limited on the background of a very high degree of heterogeneity
in clinical presentation and o utcome. Experimental chronic liver injury and
cancer have been used extensively to mimic the human d
 isease. In particular,
mouse studies have advanced the field due to the ability to easily manipulate
the mouse genome and transcriptome for mechanistic evaluations. In addition,
they offer the opportunity to screen new therapeutic strategies cost-effectively
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and in quick high-throughput, large-scale formats. The most commonly used
mouse models in HCC research can be categorized as chemotoxic, diet-induced,
and genetically engineered models. It is important to note that no particular
model mimics all features of a given HCC etiology or histological subtype, and
each model poses advantages and disadvantages that need to be carefully
considered.
Keywords: cirrhosis; hepatocellular carcinoma; hydrodynamic tail vein injection;
non-alcoholic fatty liver disease; non-alcoholic steatohepatitis.

INTRODUCTION
Liver cancer is the seventh most common cancer worldwide, and one of the
deadliest, with a 5-year survival rate in the range of 5–30% (1). A recent assessment by the Global Burden of Disease Cancer Collaboration revealed that 1 in
38 men and 1 in 111 women will develop liver cancer at some point in their
lives (2). In 2016, liver cancer contributed to approximately 10% of all cancerrelated deaths worldwide, ranking second in terms of the absolute number of
years of life lost, only behind lung cancer (2). High morbidity and mortality
rates underscore the need to develop platforms to identify diagnostic tools for
better and earlier detection and more effective targeted therapies, in order to
halt disease progression and improve survival of p
 atients. Therefore, appropriate preclinical models of liver cancer, in particular hepatocellular carcinoma
(HCC)—the most common type of liver cancer, representing approximately
70% of all primary liver malignancies (3, 4)—are critical research tools that
enable breakthroughs in the biology of hepatocarcinogenesis and testing of
novel therapies. Current therapy options for HCC are limited to surgical and
non-surgical ablative therapies or liver transplantation; systemic approaches,
such as treatments with multikinase inhibitors, only prolong the life expectancy
of patients by 2–3 months (5).
Human hepatocarcinogenesis typically occurs secondary to chronic liver
diseases. These include the iron overload disorder hemochromatosis, viral hepatitis, alcoholic fatty liver disease (AFLD), and non-alcoholic fatty liver disease
(NAFLD), all of which can promote steatosis, the build-up of excess fat in liver
cells, and steatohepatitis, when the condition is accompanied by inflammatory
and fibrogenic c omponents. Steatohepatitis causes cellular damage and oxidative stress and instigates the release of pro-inflammatory and pro-fibrogenic
signaling molecules, which (i) recruit immune cells to the site of injury,
(ii) induce hepatic stellate cell-mediated collagen deposition in the hepatic
wound healing response, and (iii) activate liver progenitor cells, as part of a socalled Ductular reaction, to replace lost tissue (6, 7). If injury is halted, matrix
is resorbed and normal liver architecture is restored. However, chronic pathological insults can lead to excessive fibrosis, cirrhosis, and ultimately liver
cancer (Figure 1) (7).
Micehave become the pillar for biomolecular discovery in human disease due
to numerous advantages over other model organisms (8, 9). An ever-growing list
of mouse models has been developed to study different aspects of chronic liver
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Figure 1 Progressive stages of liver disease to hepatocellular carcinoma development. Chronic
liver diseases that predispose to hepatocellular carcinoma (HCC) are generally characterized
by steatosis and hepatocellular damage or death, followed by inflammation and fibrosis.
These are initial and potentially reversible wound healing when the disease stimulus is
withdrawn. However, if the injury is persistent, liver disease may progress to end-stage
complications such as cirrhosis and HCC.

disease and progression to HCC. However, appropriate recapitulation of human
pathological features has been challenging. Furthermore, when analyzed in detail,
distinct models have been shown to induce remarkably different pathological
patterns (10). This chapter describes some commonly used as well as the most
recently developed mouse models of H
 CC. Table 1 indicates the timeframe for
HCC development and highlights some of the most prominent features and
characteristics of each model discussed in this chapter (Table 1).
A variety of strategies can be used to generate HCC in mice. These involve
administration of toxic agents, genetic modifications such as expression of oncogenes or disruption of tumor suppressor genes, cancer-promoting diets, and
xenograft implantation models. Often, multiple strategies are combined in order
to achieve clinically relevant disease progression to mimic human H
 CC. Thus, it
is important to choose the most appropriate model and time point to best answer
an underlying research question. Importantly, it may be necessary to validate
novel therapeutic targets across multiple models before they can be considered for
translation into clinical trials.

CHEMOTOXIC MODELS
Several hepatotoxins have been used to induce HCC in m
 ice. These chemicals
either cause DNA damage directly and, therefore, produce cancer-promoting
mutations, or act indirectly by facilitating clonal expansion of transformed
cells (11). Timing and reproducibility of tumor development can vary significantly between different compounds and, interestingly, between studies from
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TABLE 1

Commonly used mouse models of hepatocellular
carcinoma classified as chemotoxic, diet-based,
and genetic
HCC development
(time)

Features

References

DEN

Males >80%,
females 10–30%
incidence at
9 months.

Neutrophil infiltration, bile duct
proliferation, centrilobular hemorrhagic
necrosis, bridging necrosis. No fibrosis
or cirrhosis.

(15–18, 21–27)

CCl4

1–2 years for most
mice strains. As
early as 15 weeks
in A/J mice

Hepatocyte necrosis, steatosis, Kupffer cell
activation, immune cell infiltration.
Fibrosis precedes HCC.

(42–52)

TAA

6–12 months

Mild steatosis, centrilobular necrosis,
severe inflammation. Steady progressive
worsening of inflammatory, fibrogenic
and progenitor cell responses. Strong
centrally-driven fibrotic component,
progressing to cirrhosis prior to HCC.

(10, 58–61,
63–68,
71–74)

DEN+CCl4

100% incidence at
5 months

Similar to CCl4 alone but with shortened
HCC latency and increased presence of
progenitor cells.

(54, 55)

DEN+TAA+HFD

100% incidence at
6 months

Reliable progression to HCC with short
latency. Includes steatosis, inflammatory
and fibrogenic features.

(75)

CDE

75% incidence at
14 months

Periportal injury, severe steatosis at early
stages. Mild to moderate fibrosis, strong
liver progenitor cell component.

(10, 92, 93)

ALIOS

60% incidence at
1 year

Severe steatosis, hepatic necrosis and
inflammation. Ballooning hepatocytes
and Mallory hyaline at 16 weeks. Mild
periportal to bridging fibrosis, later liver
progenitor cell involvement.

(97, 98)

DIAMOND

89% incidence at
1 year (can be
accelerated to
6 months by
combination
with CCl4).

Pronounced hepatocyte ballooning and
progressive fibrosis at 6 months.
Strong histologic and transcriptomic
similarities with human NASH
and HCC.

(99–101)

Model
Chemotoxic

Diet

Table continued on following page
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TABLE 1

Model

Commonly used mouse models of hepatocellular
carcinoma classified as chemotoxic, diet-based,
and genetic (Continued)
HCC development
(time)

Features

References

78.6% incidence at
32–40 weeks

Several hallmarks of human NASH
(activation of hepatic stellate
cells, bridging fibrosis, immune
cell infiltration, and ballooning
hepatocytes), Highlights the role of ER
stress in HCC development.

(102, 103)

c-Myc

Incidence of 40% at
45 weeks, 60%
at 55 weeks, and
80% at 65 weeks

Mild to severe hepatic dysplasia at 2–3
months of age. First carcinogenic
lesions at about 1 year of age. Can
be accelerated by co-expression of
TGF-a and prevented by HGF. HCC
development drastically accelerated by
co-treatment with CCl4.

(109–113)

E2F1

Incidence of 33% at
1 year

Hepatic dysplasia at 2 months and
adenomas at 6 months. HCC
development accelerated by c-Myc
co-expression.

(115, 116)

Active β-catenin
+H-rasG12V

100% incidence
within 2 months
of genetic
manipulation

Active b-catenin alone does not progress
to HCC. Combination with H-rasG12V
induces rapid HCC development.
Dysplastic hepatocytes surrounded by
immune infiltration in the first 4 weeks
and multifocal nodules by 5 weeks.

(122, 123)

Apc KO

67% incidence at
8–9 months

Dose of adenoviral injections is key
(0.5 × 109 pfu). High doses increase
mortality risk. Trabecular and welldifferentiated HCCs.

(124, 125)

Trp53 KO

14–20 months

Majority of tumors display bipotential
cell phenotypes (co-expression of
hepatocyte and biliary markers).

(127, 129)

PTEN KO

Incidence of 47%
at 44 weeks and
66% at 74–78
weeks

Hepatomegaly and steatosis at 10
weeks. Features of NASH (hepatic
inflammation and fibrosis) at 40 weeks.

(132, 133)

MUP-uPA+HFD

Genetic

Active β-catenin, β-catenin gene Ctnnb1 lacking exon 3; ALIOS, American lifestyle-induced obesity syndrome; Apc,
adenomatous polyposis coli; CCl4, carbon tetrachloride; CDE, choline-deficient and ethionine-supplemented diet; c-Myc,
Myc proto-oncogene; DEN, diethylnitrosamine; DIAMOND, diet-induced animal model of non-alcoholic fatty liver disease;
E2F1, E2F transcription factor 1; HFD, high-fat-diet; H-rasG12V, substitution of glycine with valine at position 12 of human
RAS; MUP-uPA, major urinary protein-urokinase-type plasminogen activator transgenic mice; PTEN KO, liver-specific
knockout of phosphatase and tensin homolog; TAA, thioacetamide; Trp53 KO, liver-specific knockout of the mouse p53
ortholog.
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different research groups. The latter possibly reflects differences in the murine gut
microbiota, which are known to play key roles in tumor growth, as recently demonstrated in pancreatic and colon cancer as well as melanoma (12). Hepatotoxins
that are generally regarded as appropriate tumor inducers mostly recapitulate the
multistep progression stages of human HCC involving injury, steatosis, inflammation, fibrosis, and carcinogenesis. However, the degree and level of interplay of
these histological changes often varies. The most commonly used hepatotoxins to
study HCC in mice are discussed b
 elow.

Diethylnitrosamine (DEN)
DEN, also known as N-nitrosodiethylamine, is probably the most commonly used
chemical to induce liver cancer in mice and is either administered orally or
through peritoneal injection. DEN is bioactivated in centrilobular hepatocytes in
a cytochrome P450-dependent manner and produces metabolic sub-products
that have DNA alkylating properties, ultimately leading to mutagenesis (13).
Tumor incidence is reduced in CYP2 E1-deficient compared to wild-type mice,
suggesting that it may be one of the key CYP enzymes that catalyzes DEN
bioactivation (13). DEN administration also induces reactive oxygen species

(ROS) formation and oxidative stress, which constitutes an additional mechanism
by which it promotes hepatocarcinogenesis (14).
A single intraperitoneal dose of 5 mg/kg of DEN to weaning, 15-days-old male
mice is sufficient to induce hepatocarcinogenesis in approximately 80% of all
animals 9 months after induction (15). However, long-term administration or
higher doses of DEN can reach an incidence of 100% in shorter timeframes
(15–18). While DEN reliably induces HCC, dose, timing of administration,
gender, age, and strain impact the severity and timing of tumor appearance (19).
High cellular proliferation is known to enhance mutagenesis by chemical
carcinogens both in vitro and in vivo (20). Thus, in most cases, juvenile mice are
used, which display actively proliferating hepatocytes at this stage of their development. DEN treatment results in the expansion of cells with oncogenic mutations, leading to dysplastic lesions that eventually give rise to carcinomas (19).
Vesselinovitch and Mihailovich conducted an extensive dose–time response
kinetics study of DEN-induced hepatic carcinogenesis, which included evaluation of early alterations such as basophilic foci and nodules, as well as late transformation to adenomas and hepatocellular carcinoma lesions (21). Briefly, HCC
developed more reliably when DEN was administrated to younger mice (15-days
old) in a dose-dependent manner, ranging from as little as 0.625 up to 5 mg/kg
of body weight, whereas treatment of more mature mice (42-days old) with doses
up to 50 mg/kg failed to induce predictable carcinogenesis within the same observational period of up to 110 weeks (21).
Another factor influencing the carcinogenicity of DEN is the g ender. The
incidence for DEN-induced liver cancer can reach 100% for male mice, but is
only approximately 10–30% in females, indicating a gender-specific differential
response (22–27). Nakatani et a l. studied the influence of hormonal factors
and demonstrated that ovariectomy or testosterone supplementation increased
the occurrence of liver tumors in females treated with D
 EN. Furthermore,
male castration paralleled by estrogen administration resulted in a reduced
tumor incidence of 26%, similar to the prevalence observed in females (28).
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These findings in experimental liver carcinogenesis are consistent with the
observation that men are three to five times more likely to develop HCC than
women (29). The precise molecular mechanisms underlying gender imbalance
are not completely understood, but have recently been demonstrated to involve
estrogen-dependent interleukin (IL)-6 inhibition in females, and direct downstream effects in nuclear factor kappa B (NF-κB) and signal transducer and
activator of transcription 3 (STAT3) signaling, two key transcription factors in
HCC development (24, 30).
The sequence of hepatic alterations in DEN-treated mice is highly similar to
human chronic liver disease to HCC progression. During the course of their life,
mice subjected to DEN develop histological alterations that include neutrophil
infiltration, bile duct proliferation, centrilobular hemorrhagic necrosis, and bridging necrosis, all of which are observed in human HCC (31). However, the most
common histopathological features of human HCC, fibrosis, and cirrhosis (32)
are not observed with DEN administration alone (33). Indeed, 80–85% of all
cases of HCC occur in cirrhotic patients, and only about 10% of HCC cases are
reported in the absence of any chronic liver disease (34). Thus, models that
include fibrogenesis are most relevant to a better understanding of the pathogenesis of human disease. The combination of DEN with fibrotic compounds such as
carbon tetrachloride (CCl4) and thioacetamide (TAA) has been demonstrated to
better model this particular feature of HCC (35).

Carbon tetrachloride (CCl4)
CCl4 was widely used as a fumigant, cleaning product, and in fire extinguishers
until it was phased out due to safety concerns and banned worldwide in 1996,
under the “Montreal Protocol on Substances that Deplete the Ozone L
 ayer.” CCl4
is a hepatotoxin known to induce liver damage, infiltration of inflammatory cells,
and fibrosis (36). Similar to DEN, hepatotoxicity involves metabolism through
cytochrome P450 and generation of toxic metabolic sub-products in hepatocytes
(37, 38). One of them, trichloromethyl radical (CCl3*), is a highly reactive intermediary that can damage nucleic acids, proteins, and lipids, leading to impairments in diverse cellular processes (39). The main mechanism for CCl4-induced
hepatic toxicity involves exacerbated lipid peroxidation, which leads to plasma
membrane damage and secondary accumulation of lipoproteins and lipid droplets
in hepatocytes (40, 41). Thus, one advantage of the CCl4 model is that it includes
hepatic steatosis in its pathogenesis. Additionally, CCl4 promotes activation of
Kupffer cells, and this has been demonstrated to be necessary for its fibrogenic
effect (42). Pro-inflammatory signaling mediated by Kupffer cells attracts further
immune cell recruitment and infiltration, which contributes to the tissue damage
elicited by CCl4 administration (43). A single dose of CCl4 leads to centrilobular
liver necrosis, followed by tissue repair and regeneration (44). Thus, in contrast to
DEN, CCl4 must be administrated chronically and/or repeatedly in order to lead
to cycles of injury, inflammation, fibrosis, and cirrhosis, and it eventually gives
rise to HCC (11).
CCl4 is most often provided to mice as a 2–4 mL/kg 50% solution in mineral
or vegetal oil, either by gavage or intraperitoneally (45–47). However, a significant variation in dosage can be found in the literature. Inhalation exposure has
also been utilized, although this route is much less common (48). The frequency
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of doses also varies in different protocols, but generally consists of weekly,
biweekly, or three times a week administrations. While the pathology induced
by CCl4 has a prominent fibrogenic component (49, 50) and A/J male mice were
shown to present 100% incidence of HCC following a protocol of only 17-weeks
of CCl4 administration (49), the evolution to HCC generally only occurs after
long-term exposures of 1–2 years for most mouse strains (11, 51, 52). Therefore,
CCl4 is often combined with other tumor-promoting agents such as alcohol,
DEN, and others, which allow for a more timely induction of hepatic carcinogenesis, while maintaining the inflammatory and fibrogenic components that are
akin to human HCC (53). For example, a single dose of DEN at 2 weeks of age,
followed by biweekly administrations of CCl4 led to a two fold increase in carcinogenesis at 5 months of age (54, 55). Interestingly, this was associated with
significant increase in the expression of progenitor cell markers in the non-
cancerous parenchyma, suggesting the role of fibrosis in promoting cellular
alterations that lead to carcinogenesis. The presence of cells expressing progenitor features has been associated with a more aggressive tumor phenotype and
poorer outcomes in human studies (56, 57). However, the exact role of progenitor cells in the development of HCC is largely unknown and is a subject of
intense research in the field (7).

Thioacetamide (TAA)
TAA has mostly been used to induce fibrosis, cirrhosis, and liver cancer, including
cholangiocarcinoma in rats, but studies increasingly emerge on hepatic TAA
toxicity in mice (10., 58–61). TAA is an organosulfur compound that undergoes a
two-step bioactivation through the flavin-adenine dinucleotide-containing monooxygenases or cytochrome P450 via TAA sulfoxide (TASO or sulfine) to thioacetamide sulfdioxide (TASO2 or sulfene). TASO2 is a highly reactive metabolite,
which causes significant fat deposition, necrosis, and inflammatory cell aggregates
in centrilobular areas, where TAA is metabolized (10, 62). The mechanisms of
toxicity are believed to be secondary to its oxidant properties, including lipid peroxidation and production of ROS, dampening antioxidant defenses and exacerbating hepatic oxidative stress (62). In mice, it is usually administered by the addition
of drinking water at 300 to 600 mg/L, allowing for a simple model to induce
carcinogenesis without the need for regular injections (10, 60, 63). However, it can
also be administered intraperitoneally two to five times a week (63–65).
A detailed 6-week time course analysis by Köhn-Gaone and colleagues
compared the molecular and cellular injury dynamics of TAA-induced chronic
liver injury to feeding of a choline-deficient and ethionine-supplemented
(CDE) diet in mice (10). While the CDE diet induced periportal injury, steatosis, and fibrosis with a peak of all measured injury parameters in the first
2 weeks, followed by slow normalization of liver histology and function, TAA
supplementation led to progressively worsening inflammatory, fibrogenic, and
liver progenitor cell responses. Various studies have reported portal, portal–
portal, or portal–central bridging in the TAA model (63, 66–68). However, the
comprehensive time course analysis in C57BL/6 mice revealed that fibrosis is
centrally driven in TAA liver injury and progresses to cirrhosis within only
6 weeks of treatment (10). Long-term treatment with TAA alone has been
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demonstrated to induce HCC within 14–16 weeks in rats (69, 70). Murine
studies are much rarer in the literature and describe HCC development after
26 weeks to 12 months of TAA treatment (71–74). Figure 2 illustrates tumor
histology and characteristics of TAA-induced HCC development compared to
CDE-mediated HCC development in mice after 7 months of treatment.
Often, TAA has been used in combination with other methods to induce hepatocarcinogenesis in a shorter timeframe. For instance, combination of a single dose
of DEN at 14 days, accompanied by 300 mg/L of TAA in the drinking water, along
with high-fat-diet (HFD) feeding from 4 weeks of age, elicited histological features
of inflammation, steatosis, and fibrosis that were significantly exacerbated as early
as 12 weeks of treatment, and 100% of animals progressed to liver tumors by
24 weeks (75). Such combinatory strategies not only recapitulate different features
of human HCC but may also significantly reduce the time for tumor development
and have therefore become quite popular in liver cancer research (76).

DIET-INDUCED MODELS
Recent advances in antiviral therapies, which can result in permanent suppression
of hepatitis B virus (HBV) and eradication of HCV, are significantly reducing the
incidence of HCC from viral etiology (77). Furthermore, the second and most
prevalent risk factor for HCC, alcoholic steatosis, is relatively stable over time
(78). This can be attributed to observations pointing to steady or decreasing trend
of alcohol consumption per capita in most countries over the past decades (79).
Therefore, NAFLD and its advanced form, non-alcoholic steatohepatitis (NASH),
are responsible for the current and future increases in chronic liver disease and
HCC incidence worldwide (80). NAFLD is the hepatic manifestation of the metabolic syndrome and is estimated to affect an astonishing 24% of the world population (81). NAFLD is generally accompanied by obesity, insulin resistance, and
dyslipidemia. Thus, diet-induced models that manifest those metabolic alterations are well suited to represent human NAFLD-driven HCC. Noteworthy, only
a small fraction of patients with NAFLD progresses to HCC (82). The network of
factors that predict NAFLD progression to NASH and carcinogenesis are poorly
understood, hence the importance of appropriate pre-clinical models to further
our knowledge in this particular setting (83, 84).
Several diet-induced mouse models exist that induce HCC; however, not all
models replicate all the associated metabolic dysfunctions that are characteristic
of human N
 AFLD. Feeding rodents a diet deficient in choline (CD), for instance,
is known to induce hepatic steatosis and progression to HCC (85). This has first
been observed in rats (86, 87) and confirmed in a number of mouse strains (88).
Mechanistically, choline deficiency leads to defects in phospholipid synthesis,
lipoprotein secretion, oxidative damage, endoplasmic reticulum (ER) stress, and
cell death (85). Diets that combine choline with methionine deficiency (MCD)
induce even more severe pathology, characterized by steatohepatitis within 1–2
weeks and fibrosis by 8–10 weeks of feeding (89, 90). However, both CD and
MCD are not accompanied by other physiological hallmarks of the metabolic
syndrome, namely dyslipidemia, glucose intolerance, and insulin resistance
(91). Furthermore, these diets promote severe body weight loss and morbidity,
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Figure 2 Histology and cellular characterization of CDE- and TAA-induced tumors. (A) Gross
liver morphology assessment of C57BL/6J mice treated with CDE or TAA for 7 months
demonstrates the development of advanced tumors. Hematoxylin and eosin (H&E) stains
reveal the presence of a great variety of neoplastic changes and nodules. TAA-induced
tumors comprise large polygonal cells with abundant eosinophilic cytoplasm and atypical
stripped nuclei as well as moderate basophilic cell infiltrates. Similar characteristics are
identified in CDE-induced tumors, although with weaker eosinophilic cytoplasm and
enriched small basophilic cells. An altered stromal network of collagen III-composing fibers
demonstrates the characteristic thickening of hepatic cell plates and diffuse reticulin
structures within tumors. Reticulin crowding at the interface of tumorous and non-tumorous
tissue indicates invasive tumor growth into the surrounding tissue. (B) Immunohistochemical
staining of both CDE- and TAA-induced tumors with the biliary and liver progenitor cell
markers cytokeratin 19 (CK19) and CK7 and the hepatocellular carcinoma (HCC) marker
carbamamoyl phosphate synthetase I (CPS1) identifies the tumors as HCC with biliary and
progenitor proliferation almost exclusively in extra-tumoral tissue. (C) Fluorescent labeling
of the cellular components of the injury and regeneration niche, which hosts panCK+ biliary
and progenitor cells (green), alpha-smooth muscle actin (aSMA)+ hepatic stellate cells (red)
and CD45+ inflammatory cells (white), illustrates the cells’ close spatial relationship and
potential for cellular cross-talk in the tumor-surrounding tissue of CDE and TAA mice. NT,
non-tumor; T, tumor.
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and thus, they are generally not suitable for long-term experiments leading up to
HCC. In order to significantly reduce the time to carcinogenesis, ethionine, a
non-proteinogenic cytotoxic methionine analogue, can be added to the CD diet
(CDE) and induce severe hepatic inflammation with a strong proliferation of
liver progenitor cells and activation of fibrosis-driving hepatic stellate cells in as
early as 2 weeks of feeding (92). Long-term CDE feeding of C57Bl/6 mice
induced HCC in 75% of animals, whereby tumor development was significantly
inhibited following treatment with the multi-tyrosine kinase inhibitor imatinib
mesylate (93). Features of CDE-induced HCC after 7 months of treatment are
demonstrated in Figure 2 in comparison with tumors provoked by TAA
administration.
The HFD model involves feeding animals ad libitum diets containing a total of
45% to75% calories intake derived from fats (94). Several formulations exist in
which the types and percentages of fats vary significantly (95). In this model,
hepatic steatosis, characterized by increased liver triglyceride accumulation and
fatty acid synthesis, is accompanied by other features of the metabolic syndrome
such as obesity, glucose intolerance, and insulin resistance (96). It is a very reliable
model to induce simple hepatic steatosis; however, in most mouse strains, no
additional liver damage and inflammation, neither development to HCC, are
observed (83).
To produce a model that more closely resembles the human disease, Tetri et a l.
developed a formulation containing nutrients commonly found in fast foods and
kept mice under conditions designed to encourage sedentary behavior, the socalled American Lifestyle-Induced Obesity Syndrome (ALIOS) model (97). The
formulation included trans-fats and high-fructose corn syrup, in addition to
removal of cage racks to promote low energy expenditure. After 16 weeks under
this regime, mice developed severe hepatic steatosis, associated with necrosis and
inflammation. Histological features of human NASH such as ballooning hepatocytes and Mallory hyaline were also d
 escribed. Fibrogenesis was not detected
histologically; however, procollagen mRNA expression was found to be upregulated, suggesting that fibrosis might develop at time points later than 16 weeks
(97). Consistent with this hypothesis, a separate study used 12-month exposure
to the ALIOS protocol and revealed fibrosis with severity ranging from mild periportal to bridging fibrosis (98). These observations were accompanied by substantial activation of the liver progenitor cell niche, which was evidenced through
increased numbers of cells positive for pan-cytokeratin (panCK) and sex-
determining region Y-box 9 (Sox9) throughout the 
parenchyma. HCC was
observed in 60% of all ALIOS mice at 12 months (98). These studies demonstrate
that diet and lifestyle interventions are sufficient for the induction of NASH and
hepatocarcinogenesis in mice. Future studies are necessary to assess the level of
similarities between the genetics and transcriptomics of carcinogenesis observed
in ALIOS mice compared to human HCC.
Another western diet model, comprised of high cholesterol, high saturated fat,
and high fructose, has been shown to promote NASH, which was characterized by
pronounced hepatocyte ballooning and progressive fibrosis after 6 months of
feeding (99). No HCC was observed at 6 months, but it resulted in 89% incidence
of spontaneous HCC after 12 months of feeding to a stable isogenic cross between
C57BL/6J and S129 mice (100). Interestingly, this model, named Diet-Induced
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Animal Model Of Non-alcoholic fatty liver Disease (DIAMOND), presented
remarkable histologic and transcriptomic similarities with human NASH and
HCC. Tsuchida et a l. recently demonstrated that the same diet, combined with
low weekly doses of CCl4, can develop rapid progression to stage 3 fibrosis and
HCC within 12 and 24 weeks, r espectively. The pathology closely mimicked histological, immunological, and transcriptomic features of human NASH, thus representing a rapid induction model suitable to study hepatocarcinogenesis in a
clinically relevant setting (101).
Most recently, another diet-induced model of NASH-driven HCC was established through genetically induced predisposition to H
 CC. Feeding of a HFD to
major urinary protein (MUP)-urokinase-type plasminogen activator (uPA) transgenic mice, which overexpress uPA specifically in hepatocytes, induced liver disease that recapitulated several hallmarks of human NASH and reliable progression
to HCC (102). In comparison with HFD-fed control wild-type animals, MUP-uPA
mice displayed increased activation of hepatic stellate cells as well as upregulation
of collagen and other fibrogenic m
 arkers. Immune cell infiltration, bridging fibrosis, and ballooning hepatocytes were all present in MUP-uPA mice at 24 weeks
after diet initiation. Hepatocarcinogenesis was observed at 32–40 weeks of HFD
feeding in about 78.6% of these animals. The mechanism of disease progression
involved excessive ER stress, induced by hepatocyte overexpression of uPA and
exacerbated by HFD, as well as tumor necrosis factor (TNF)-dependent inflammation (102). This model was later used to demonstrate the key role of caspase-2,
downstream of TNF and ER stress, in mediating the activation of sterol regulatory
element-binding proteins (SREBP), recognized to participate in NASH development (103).

GENETICALLY ENGINEERED MODELS
Human HCC is known to have a very high level of inter- and intra-tumor genetic
heterogeneity (104). Illustrating this concept, a study by Schulze and colleagues
employed exome sequencing analysis and identified mutations in 161 distinct
putative driver genes in a cohort of only 243 hepatic tumors (105). In addition, a
recent study published by the Cancer Genome Atlas Research Network investigated 383 HCC cases by whole-exome sequencing and DNA copy number analyses and assessed 196 HCC samples for their DNA methylation, RNA, miRNA, and
proteomic status. The comprehensive data set, coupled with robust statistical
power by the large investigated cohort, enabled the identification of various
molecular signatures, which may be therapeutically targeted in different HCC
subgroups (106). The individual roles of many of the identified genes and pathways in hepatocarcinogenesis have been, and continue to be, determined using
mouse genetics. Such models are excellent tools to investigate the discrete effects
of candidate oncogenes or tumor suppressor genes in HCC. The number of genetically engineered mouse models of HCC is very large and continuously expanding.
Moreover, comprehensive reviews describing available models have been published elsewhere (107). The scope of this chapter is to present a few of the most
commonly used and well-characterized genetic models in d
 etail.
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c-Myc
The transcription factor c-Myc controls numerous cellular processes, including
cell cycle progression and p
 roliferation. Mutations that activate c-Myc are known
to be highly associated with carcinogenesis in human HCC (108). Transgenic
mice, overexpressing c-Myc specifically in the liver, develop hepatic tumors with
a relatively long latency of approximately 12–15 months (109–111). Tumor incidence is of about 40% at 45 weeks of age, 60% at 55 weeks, and 80% at 65 weeks
(111). To limit oncogene expression to the hepatic tissue, the albumin promoter
has most commonly been utilized due to its specificity to hepatocytes (11). When
c-Myc was combined with transgene expression of growth factors such as transforming growth factor alpha (TGF-α) and hepatocyte growth factor (HGF), opposing results were obtained. Combination with TGF-α led to a significant acceleration
of the neoplastic development, with tumors developing before 16 weeks of age
(110). In contrast, HGF prevented malignant transformation when investigated in
a similar setting (112). Interestingly, the kinetics of carcinogenesis induced by
c-Myc can be drastically accelerated to under 40 days by co-treatment with the
hepatotoxins CCl4 or 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) (113). An
elegant study by Shachaf and colleagues demonstrated that inactivation of the
MYC oncogene resulted in tumor regression, accompanied by differentiation of
the tumor cells into hepatocytes and cholangiocytes. The tumors lay dormant
until c-Myc was reactivated in cells the authors proposed to be cancer stem celllike cells (114).
The E2F transcription factor 1 (E2F1) has also been identified as frequently
dysregulated and/or mutated and was demonstrated to induce HCC in mice upon
hepatic transgenic overexpression (115, 116). E2F1 mice showed signs of hepatic
alterations as early as 2 months of age, with most animals developing adenomas
at 6 m
 onths. However, tumors progressed to HCC only in one-third of experimental animals at 1 year of a ge. Co-expression of E2F1 and c-Myc further accelerated the appearance of focal lesions and severe dysplasia, leading to earlier
development of HCC as compared to either of the oncogenes alone (117).

Wnt/β-catenin
Wnt/β-catenin signaling controls a plethora of cellular communication networks
in embryonic development and demonstrates key roles in regulating stemness and
cell differentiation in health and disease (118). Pathological alterations of this
pathway are known for its involvement in many human cancers, including liver
cancer (118, 119). Beta-catenin is one of the key effectors of Wnt signaling, and
its gene CTNNB1 is the most frequently found mutated component of this pathway in human HCC (120). Altered activity of β-catenin, as evidenced by mutation
or nuclear translocation, was observed as an early event in hepatocarcinogenesis
driven by distinct genetic models (121). Yet, constitutive activation of β-catenin
through deletion of its regulatory domain was not sufficient to promote hepatic
tumorigenesis by itself (122). When combined with oncogenic H-ras (H-rasG12V),
however, β-catenin activation resulted in aggressive HCC development with
100% incidence within 3–4 months following the genetic manipulation (123).

81

82

Carlessi R et al.

Interestingly, the most commonly used approach to induce hepatic β-catenin activation in mice has been the selective Cre-Lox disruption of its negative regulator,
adenomatous polyposis coli ( Apc). This indirect approach for the stabilization of
active β-catenin was shown to lead to spontaneous hepatocyte hyperplasia and
67% incidence of HCC in the surviving animals following 8–9 months of model
establishment (124). Tumors generated through this model have recently been
shown to possess a unique metabolic signature, characterized by exacerbated fatty
acid utilization (125), suggesting that inhibition of fatty acid oxidation could be a
potential therapeutic approach for β-catenin-induced HCC.

Liver-specific knockout models
Liver-specific knockout models of tumor suppressor genes have also been developed and utilized either alone or in combination with other insults to study liver
cancer. The TP53 gene that encodes for the tumor suppressor p53 is found
mutated in most human cancers, including HCC (126). P53 knockout mice displayed a significantly increased hepatocyte proliferation rate and LPC-like cells in
periportal liver regions (127). In addition, p53-/-LPCs isolated from these mice
and injected subcutaneously into athymic nude mice generated tumors with a
HCC morphology (128). In a separate study, the homozygous deletion of Trp53
(the mouse ortholog), specifically in the liver, led to HCC formation after
14 months of age (129). The authors also showed that p53 deletion gave raise to
tumors with a bilineal phenotype and increased proliferation of liver progenitor
cells. These observations support a model in which loss of function of p53 may
promote HCC through an increase in the proliferative capacity of progenitor c ells.
Another ubiquitously expressed tumor suppressor gene frequently found
mutated or downregulated in human HCC is phosphatase and tensin homolog
(PTEN) (130, 131). Its phosphatase activity inhibitsphosphatidylinositol-3-
kinases (PI3K) and consequently suppresses downstream protein kinase B (PKB/
Akt) and mammalian target of rapamycin (mTOR) growth-promoting signaling.
Horie et a l. generated a liver-specific PTEN knockout model through the crossing
of albumin promoter Cre mice with PTEN-floxed mice (132). The resulting
conditional PTEN knockout mice showed hepatomegaly and steatosis as early as
10 weeks of a ge. At 40 weeks, features of NASH including hepatic inflammation
and fibrosis were observed. This model also reliably progressed to tumorigenesis,
although with a long latency. The incidence of hepatic adenomas was 47% at
44 weeks, and by 74–78 weeks, 66% of animals displayed HCC (132). The mechanism of carcinogenesis driven by PTEN disruption has later been addressed. It
involves hepatic injury-dependent expansion of epithelial cellular adhesion
molecule (EpCAM), alpha-fetoprotein (AFP), and cytokeratin 19 (CK-19) positive
progenitor cells (133).

Hydrodynamic tail vein injection (HTVI) models
Traditionally, genetic modifications, such as gene knockouts, knockins, and transgene overexpression, were introduced in the germline of parent mouse strains to
produce whole body genetic alterations (134). This approach has been extensively
used in HCC research; however, advances in genetic manipulation tools, such as
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Cre-Lox recombination, have allowed for a much more precise spatial and
temporal control of candidate genes expression, and their utilization has become
widespread (135). Notably, this kind of approach has been used to produce conditional liver-specific genetic manipulations, overcoming the problem of embryonic lethal gene mutations as well as restricting phenotypes to the hepatic tissue.
Nonetheless, these are both expensive and time-consuming s trategies.
A simple and inexpensive alternative method to transfect and gene-edit
hepatocytes in vivo is represented by hydrodynamic tail vein injection (HTVI) of
“naked” plasmid DNA (non-viral vector, not associated with protective proteins
or lipids) directly into the liver of adult mice (136, 137). The technique consists
of rapid injection of a large amount of plasmid DNA (about 50 μg in a volume of
saline that signifies 10% of the body weight of the injected mouse) into the mouse
lateral tail vein (138). HTVI results in transient heart dysfunction and fluid accumulation in the inferior vena cava. The enormous hydrodynamic pressure then
forces the fluid into the liver in a retrograde movement, enlarges the liver, and
pushes the plasmid DNA into hepatocytes via enlarged sinusoidal fenestrae and
transient membrane pores (139), with transfection efficiencies ranging from
around 10 to 40% of all hepatocytes (136, 140). While the liver is primarily targeted, other organs including heart, kidney, lung, and spleen are also affected by
HTVI; however, to only 0.1% of the levels achieved in the liver (138, 141). One
caveat of HTVI is that the expression of transfected genes is transient, peaking
within 24 h, but dropping dramatically thereafter (142). In order to circumvent
this pitfall, HTVI has been combined with DNA recombination technologies such
as Cre-Lox, sleeping beauty (SB) transposase, and CRISPR-Cas9, allowing for
genomic integration and continuous expression of genetic modifications. HTVI
has been used increasingly to study genetic factors influencing HCC biology, and
a variety of HCC models have recently been developed using this approach.
Particularly, HTVI permits the assessment of more than one genetic alteration at
the same time and therefore the investigation of the combinatory effects of targeting multiple pathways s imultaneously. A number of models created through HTVI
are discussed below and are summarized in Figure 3.
The PI3K/AKT/mTOR pathway is central in the regulation of hepatocyte cell
metabolism, growth, and proliferation (143). Upregulation of this pathway is frequently observed in human HCC (144, 145) and is associated with poorer outcomes (146). As described before, conditional liver knockout of PTEN, a negative
regulator of this pathway, induces NASH-like liver disease and HCC in mice
(132). HTVI was used to introduce a constitutively active form of AKT (myristoylated AKT) that induced HCC about 6 months post-injection (147). Wild-type
mice were co-injected with SB transposase and active AKT vectors for somatic
integration. Disease progression resembled that of PTEN knockout mice, with
increased lipogenesis and upregulation of genes involved in fatty acid synthesis
(147). Importantly, the expression of transfected AKT was observed in relatively
few cells, which were surrounded by non-transfected hepatocytes. This is considered to be an advantage of HTVI, in that it better resembles human liver cancer,
where only a limited number of foci are believed to give rise to HCC (140).
It was later reported that co-injection of AKT along with H-rasG12V significantly increases the kinetics of liver tumor development, with 100% of injected
animals presenting tumors within 4 weeks post-injection (148). Similar kinetics
were observed when AKT was co-expressed with active β-catenin (149).
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Fast (5-8s) injection into
lateral tail vein
(~50 µg plasmid DNA
in 2.5 ml saline)
Cre-Lox, sleeping beauty
transposase, and/or
CRISPR-Cas9-based
plasmids

Myristoylated AKT [HCC in 6 months (145)]
Myristoylated AKT + H-rasG12V [HCC in 4 weeks (146)]
Myristoylated AKT + active β-catenin [HCC in 4 weeks (147)]
H-rasG12V in p19ARF KO background [HCC in 6 weeks (148)]
H-rasG12V + Trp53 shRNA [HCC in 4 weeks (149)]
CRISPR-Cas9-mediated PTEN and Trp53 double KO
[HCC in 3 months (153)]
Variable latency depending on model
Co-injection of luciferase expression cassette
allows for in vivo monitoring of tumour growth
by bioluminescence imaging (BLI) (149)

Figure 3 Hydrodynamic tail vein injection models of hepatocellular carcinoma. Plasmid DNA
containing Cre-Lox, sleeping beauty transposase, and/or CRISPR-Cas9-based recombination
sequences along with key oncogenes or tumor suppressor disruption sequences is injected
into the lateral tail vein of young mice. HCC develops with variable latency depending on the
chosen genetic manipulation, as indicated. Co-injection of luciferase expression cassette
allows for in vivo monitoring of tumor growth by bioluminescence imaging (BLI). HCC,
hepatocellular carcinoma; KO, knockout.

Interestingly, injection of H-rasG12V alone did not lead to HCC (148, 150).
However, when expressed in p19 Arf knockout mice, H-rasG12Vinduced HCC in
all mice within 6 weeks that otherwise did not develop with simple disruption of
this positive regulator of p53 (150). In a similar way, H-rasG12V combined with a
shRNA construct targeting p53 led to hepatocarcinogenesis within only 4 weeks
(151). This study also demonstrated that oncogenic vectors can be combined
with a SB transposase plasmid containing a firefly luciferase expression cassette,
allowing for tumor growth to be monitored non-invasively over time through
bioluminescence imaging. Altogether, these results highlight the suitability of
HTVI to create models that allow for the utilization of synergistic pathways in
promoting HCC for rapid induction studies and proof-of-concept therapeutic
interventions.
Notably, the SB transposase system permits efficient genomic recombination of
exogenous sequences; however, this approach is not specific in terms of the integration site (152). Recombination can potentially occur virtually anywhere in the
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genome, causing undesired disruption of off-target genes (153). The CRISPRCas9 system, on the other hand, offers sequence-specific direct editing of DNA
with only rare off-target mutations (154). In a proof-of-concept study, Xue et a l.
utilized HTVI to generate CRISPR-Cas9-mediated knockouts of PTEN and p53,
or combinations of the two, that phenocopied the traditional conditional liver
knockouts of these genes (155). PTEN and/or p53 disruptions were shown to be
present in 3 to 6% of all hepatocytes. At 3 months post-injection, all animals with
double disruptions developed liver tumors (155). The same approach was used to
target β-catenin and simultaneously introduced a constitutively active version of
it. This notoriously less-efficient event, observed in only 0.5% of all hepatocytes,
however, demonstrated that CRISPR-Cas9 can also be used to introduce gain-offunction mutations, providing a highly specific and low off target method for the
evaluation of novel gene roles in HCC development (155). Consequently, CRISPRCas9 combined with HTVI has been increasingly utilized for HCC research in
recent years (156–158).

CONCLUSION
HCC poses a global health challenge in terms of prevention, diagnosis, and
treatment. While epidemiological studies can provide information on associations
between HCC and variables that influence its natural history, the progression of
interventions into clinical practice requires demonstrated benefits and safety from
carefully designed in vivo models such as the mouse models described h
 ere.
A large variety of experimental chronic liver injury and HCC models are currently
available, each with particular characteristic features, mimicking diverse etiologies and disease progression p
 atterns. Selection of the most appropriate animal
model allows for the study of disease context-specific as well as common carcinogenic mechanisms and screening of novel therapeutic targets for clinical
translation. Until the tyrosine kinase inhibitor sorafenib was approved for unresectable HCC in 2007, there was no FDA-approved therapies available for patients
in advanced-stage chronic liver disease. The improved understanding of the
molecular mechanisms of HCC, primarily obtained from several of the animal
models herein described, has culminated in the development of current targeted
therapies, including sorafenib and regorafenib. Several other agents have been
tested, or are currently under clinical evaluation, and will hopefully contribute to
improved HCC outcomes in the years to come. There is no perfect animal model
for human disease; however, mouse models are still invaluable and will continue
to form the cornerstone of preclinical studies, designed to delineate interventions
that are effective and safe in the future.
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